Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Synthesis method of cediranib

A synthesis method and technology of cediranib, applied in the field of medicinal chemistry synthesis, can solve the problems of carbonization of products, difficult purification of products, large solid residues and the like

Inactive Publication Date: 2012-07-25
CHEMPROSPECT PHARMTECH
View PDF7 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The zinc powder reduction used in this method is difficult to post-process and produces a large amount of solid residue. Using formamide as a cyclization reagent requires high temperature (190°C) and long-term reaction, which is easy to carbonize the product and generate impurities.
WO2006117552A1 uses iron powder for reduction, and also uses formamide as a cyclization reagent, which will lead to difficult post-processing and difficult purification of the product

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Synthesis method of cediranib
  • Synthesis method of cediranib
  • Synthesis method of cediranib

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0086] 1) Chemical synthesis of ethyl 2-(2,3-difluoro-6-nitrophenyl)-3-acetoacetate (X1)

[0087] Dissolve 68g (1mol) of sodium ethoxide in 300ml of anhydrous tetrahydrofuran, stir mechanically and cool down to 10°C, add 130g (1mol) of ethyl acetoacetate, dropwise complete within about 1 hour, and control the temperature below 35°C. Dissolve 88.5 g (0.5 mol) of 1,2,3-trifluoro-4-nitrobenzene in 200 ml THF, and add dropwise into the above reaction solution under ice-cooling conditions. The reaction was naturally raised to room temperature and stirred for 5 h, and the completion of the reaction was monitored by TLC.

[0088] Pour 500ml of 1N hydrochloric acid aqueous solution to quench, extract with ethyl acetate (1L*3), combine the organic phases, wash the organic phase with saturated brine, spin dry to obtain 241g of product, yield: 84%.

[0089] The structure of the product was confirmed by NMR:

[0090] 1 H NMR Spectrum (CDCl 3 ): δppm 13.21(s,1H),7.87(m,1H),7.30(t,1H),4.2...

Embodiment 2

[0146] As described in Example 1, the difference is that sodium hydride is used in step (1), the molar ratio of the reaction materials is the same, and 125 g of the product is obtained by the reaction, and the yield is 44%.

Embodiment 3

[0148] As described in Example 1, the difference is that potassium tert-butoxide is used in step (1), the molar ratio of the reaction materials is the same, and 153 g of the product is obtained after the reaction, and the yield is 54%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a preparation method of cediranib, which comprises the following steps of using trifluoro-nitrobenzene as a raw material and performing acetyl methyl adding, substitution, cyclization and protection to obtain a segment 1; and then using methyl vanillate as the raw material, performing benzyl bromine protection, nitro adding, reduction, unique cyclization and chlorination to obtain a segment 2; and performing nucleophilic substitution and deprotection on the two segments to obtain the final product cediranib. Compared with other methods, the preparation method of the cediranib has the advantages of mild reaction condition, high yield and scale amplification, and raw materials can be obtained easily.

Description

technical field [0001] The invention relates to the preparation of cediranib (Cediranib), which belongs to the field of pharmaceutical chemical synthesis. Background technique [0002] Cediranib (tentative trade name Recentin), also known as AZD2171, is a potent inhibitor of pan-vascular endothelial growth factor (pan-VEGF) receptor tyrosine kinase. This is an oral chemotherapy drug that AstraZeneca is developing as a possible treatment for cancer. [0003] In antitumor treatment, chemotherapy is a widely used systemic treatment, which can be used alone or in combination with other methods, even for middle and advanced cancers that cannot be treated by surgery. In recent years, with the rapid development of chemotherapy pharmacology and cell molecular biology, chemotherapy drugs are transitioning from traditional cytotoxic drugs to new anticancer drugs with multiple links and new targets, and cancer cell differentiation inducers, telomerase inhibitors, etc. agent, tumor ge...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D403/12
Inventor 李宏松张淑娴欧贤飞程哲超
Owner CHEMPROSPECT PHARMTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com